EGLN1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8496	0.66	18/20
SCHEMBL8497	0.66	18/20
SCHEMBL7976	0.63	17/20
SCHEMBL7977	0.63	17/20
SCHEMBL7717	0.55	17/20
SCHEMBL7718	0.55	17/20
SCHEMBL7956	0.54	17/20
SCHEMBL7957	0.54	17/20
SCHEMBL244112	0.68	16/20
SCHEMBL71030	0.50	11/20
SCHEMBL171037	0.55	10/20
SCHEMBL69286	0.81	7/20
SCHEMBL5592	0.54	7/20
SCHEMBL71738	0.51	7/20
SCHEMBL10488	0.50	7/20
SCHEMBL10489	0.50	7/20
SCHEMBL69243	0.47	7/20
Succinic Acid (SCHEMBL35204)	0.75	6/20
Succinic Acid (SCHEMBL209622)	0.69	6/20
Levulinic Acid (SCHEMBL113572)	0.64	6/20

Clinical trials — most relevant to EGLN1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)	PHASE2	UNKNOWN
Study of the Effects of Iron on Lung Blood Pressure at High Altitude	PHASE2	WITHDRAWN
Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients	PHASE2	COMPLETED
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer	PHASE2	COMPLETED
Carnosine for Peripheral Vascular Disease	PHASE2	UNKNOWN
Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing	PHASE1	WITHDRAWN
Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment	PHASE1	COMPLETED
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases	PHASE1	COMPLETED
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Drivers of Hypoxia-induced Angiogenesis in Tumor Development	nan	UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma	nan	RECRUITING
Selecting Hypoxic Tumours for Treatment Modification	nan	RECRUITING
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions	nan	RECRUITING
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock	nan	COMPLETED
Study of the Effects of Iron Levels on the Lungs at High Altitude	nan	COMPLETED
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure	nan	UNKNOWN
Effects of High Altitude on AMPK Activation	nan	RECRUITING
Hypoxia Inducible factor1-Alpha Genetic Polymorphism of Obstructive Sleep Apnea	nan	UNKNOWN
High Altitude Medical Research Expedition Himlung 2013 - a Study of Human Adaption to Hypoxia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EGLN1 binder may also engage these)

Protein	Name	Similarity
Q91YE2	—	0.993	Q91YE2 →
P59722	—	0.993	P59722 →
Q91YE3	—	0.992	Q91YE3 →
EGLN2	Prolyl hydroxylase EGLN2	0.989	landscape →
Q6AYU4	—	0.988	Q6AYU4 →
PAK4	Serine/threonine-protein kinase PAK 4	0.981	landscape →
Q8BTW9	—	0.981	Q8BTW9 →
Q922K7	—	0.980	Q922K7 →
KDM4B	Lysine-specific demethylase 4B	0.980	landscape →
A2WYE9	—	0.980	A2WYE9 →
Q6IV56	—	0.980	Q6IV56 →
UHRF1	E3 ubiquitin-protein ligase UHRF1	0.979	landscape →
E7EZF3	—	0.979	E7EZF3 →
Q9UPV7	—	0.979	Q9UPV7 →
O08919	—	0.979	O08919 →
P03177	—	0.979	P03177 →
Q17QP1	—	0.979	Q17QP1 →
P0DO23	—	0.979	P0DO23 →
Q0DCT8	—	0.979	Q0DCT8 →
A0A0R4IKJ1	—	0.979	A0A0R4IKJ1 →
Q7TPK1	—	0.979	Q7TPK1 →
Q5R8Z4	—	0.979	Q5R8Z4 →
D3YWQ0	—	0.978	D3YWQ0 →
MKNK1	MAP kinase-interacting serine/threonine-protein kinase 1	0.978	landscape →
Q99PI5	—	0.978	Q99PI5 →
Q3U2K5	—	0.978	Q3U2K5 →
Q3ULB5	—	0.978	Q3ULB5 →
O70441	—	0.978	O70441 →
Q8JZP2	—	0.978	Q8JZP2 →
Q9TUI4	—	0.978	Q9TUI4 →